All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.  View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2025: Top abstracts in Lymphoma and CLL

By Dylan Barrett

Share:

Jun 9, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma and CLL

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, June 12–15, 2025, Milan, IT, the Lymphoma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in lymphoma and chronic lymphocytic leukemia (CLL). 

EHA 2025: Top abstracts in Lymphoma and CLL

Thursday, June 12, 2025 

Abstract # Title Speaker Time (CEST)
S190Cyclophosphamide is superior to methotrexate in previously untreated large granular lymphocyte leukemia. Final results of a prospective, multicentric, phase II randomized controlled trial CT01976182Thierry Lamy17:00–17:15
S191The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: Final analysis from the phase 3 GAIA/CLL13 trialMoritz Fürstenau17:15–17:30  
S225Acimtamig (AFM13) in combination with AlloNK® (AB-101) in patients with relapsed or refractory classical Hodgkin lymphoma: Results from the dose finding phase of the LuminICE-203 phase 2 studyAmitkumar Mehta17:00–17:15  
S226Long-term responses and late toxicities in advanced-stage Hodgkin lymphoma: A 10-year update of the HD0607 trialAlessandro Cellini17:15–17:30
S229Elevated serum TARC after one cycle of BV-AVD correlates with adverse prognosis despite escalation to BrECADD in advanced stage Hodgkin lymphoma: Biomarker analysis from the EORTC-1537-COBRA trialSophie Teesink18:00–18:15
S240Prospective validation of end of treatment ctDNA-MRD BY PhaseD-Seq in DLBCL patients from a national HOVON trialMartine Chamuleau17:00–17:15
S241Frail is not fail: Comorbidities do not affect non-relapse mortality and safety in patients with LBCL treated with CAR-T therapyEugenio Galli17:15–17:30

 

Friday, June 13, 2025 

Abstract # Title Speaker Time (CEST) 
S235Long-term efficacy and survival outcomes with odronextamab for patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the phase 2 ELM-2 studyStefano Luminari17:00–17:15
S236A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory B-cell lymphomaSaurabh Dahiya17:15–17:30
S237Real-world effectiveness and safety outcomes among key subgroups of second-line (2L) axicabtagene ciloleucel (axi-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)Dasom Lee17:30–17:45
S238High CD70 expression in newly diagnosed follicular lymphoma is linked to relapse and presents opportunities for dual CD19-CD70 CAR-T therapyMaria Ros17:45–18:00
S239A global phase 1b study of JNJ-90014496, a CD19/CD20 bi-specific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)Matthew Ku18:00–18:15

 

Saturday, June 14, 2025 

Abstract # Title Speaker Time (CEST) 
S101Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trialMatthew Matasar12:00–12:15
S104Minor independent clones in patients with chronic lymphocytic leukemia have a CLL-biased biological signature: Implications for disease ontogeny and evolutionIan Márquez-López12:45–13:00
S230Tafasitamab (tafa) plus lenalidomide (len) and rituximab (R) for patients with relapsed or refractory follicular lymphoma (R/R FL): Results from the phase 3 inMIND studyMarek Trneny17:15–17:30
S231Updated efficacy & safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia (WM): Ongoing phase (Ph) 1 CaDAnCe-101 study resultsAnna Maria Frustaci17:30–17:45
S232MorningSun: Open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab (Mosun SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL)John M. Burke17:45–18:00
S233Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trialMartin Dreyling17:00–17:15
S234Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphomaRaul Cordoba18:00–18:15

 

Sunday, June 15, 2025 

Abstract # Title Speaker Time (CEST) 
LB4003Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclaxDaisy Diaz Rohena09:45–10:00
S155Ibrutinib plus venetoclax with MRD-guided duration of treatment is superior to both continuous ibrutinib monotherapy and FCR for previously untreated CLL: Report of the phase III UK FLAIR studyTalha Munir11:00–11:15
S156Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE studyPaolo Ghia11:15–11:30
S158Updated efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the ongoing phase (ph) 1 CaDAnCe-101 studyLydia Scarfò11:45–12:00
S159Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responsesChan Cheah12:00–12:15
S245First disclosure of epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2Raul Cordoba11:00–11:15  
S246A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 (EZH2), in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)Yuqin Song11:15–11:30  
S247Durable efficacy with fixed-duration epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) for 1L diffuse large b-cell lymphoma (EPCORE NHL-5)Daniel Kerr11:30–11:45
S248Frontline phase II rituximab-polatuzumab-glofitmab (R-Pola-Glo) trial demonstrates a manageable safety profile and high response rates in elderly and medical unfit patients with aggressive lymphomaThomas Melchardt11:45–12:00
S249Excellent outcome with interim PET adapted treatment reduction in elderly DLBCL pts with favourable prognosis: Results of 288 pts treated in optimal>60 trial of the DSHNHL/GLAViola Pöschel12:00–12:15
S280Enhanced CAR T-cell expansion and durable complete responses with NKTR-255 plus lisocabtagene maraleucel in relapsed/refractory large B-cell lymphomaAlexandre Hirayama11:00–11:15
S281Low rates of high-grade toxicities with GLPG5101, a fresh, stem-like, early memory phenotype anti-CD19 CAR T-cell therapy in patients with non-Hodgkin lymphoma in the ATALANTA-1 studyPim G. N. J. Mutsaers11:15–11:30

 

Posters 

Abstract # Title Speaker Time (CEST) 
PF572Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trialPaolo GhiaFriday, 18:30
PF869PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: Long-term follow-up of the GATLA LH-05 trialAstrid PavlovskyFriday, 18:30
PS1565SEQUOIA 5-year follow-up in Arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Mazyar ShadmanSaturday, 18:30
PS1866Real-world evidence of brentuximab vedotin (BV) consolidation after autologous transplant (ASCT) in relapsed/refractory Hodgkin lymphoma (RRHL): 2-year follow-up of GATLA RRHL studyAstrid PavlovskySaturday, 18:30
PS1870PD-1-based salvage therapy for relapsed and refractory Hodgkin lymphoma: A multicenter real-world analysisHishan TharmaseelanSaturday, 18:30
PS1898Patient-reported outcomes in patients with relapsed/refractory follicular lymphoma treated with epcoritamab within the entire study cohort and in patients with symptoms at baselineP. Connor JohnsonSaturday, 18:30
PS1909Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLOGareth GregorySaturday, 18:30
PS1957Updated safety run-in results from LOTIS-5: A phase 3, randomized trial of loncastuximab tesirine with rituximab versus immunochemotherapy in patients with R/R DLBCL/HGBLCarmelo Carlo-StellaSaturday, 18:30
PS1968Match-adjusted comparative analysis of epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ transplant-eligible patients with diffuse large B-cell lymphomaJustin DarrahSaturday, 18:30
PS21504-year update of phase 2 ELARA trial: Clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL)Catherine ThieblemontSaturday, 18:30

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2025BGB-16673BendamustineOdronextamabChronic lymphocytic leukemiaMantle cell lymphomaDiffuse large B-cell lymphomaFollicular lymphoma Small lymphocytic lymphomaT-cell large granular lymphocytic leukemiaSonrotoclaxLarge B-cell lymphomaDexamethasoneBleomycinClassical Hodgkin lymphomaEpcoritamabVenetoclax PrednisoneLenalidomideCyclophosphamideMosunetuzumabMarginal zone lymphomaAcalabrutinibGlofitamabDacarbazinePolatuzumab vedotinBrentuximab vedotinDoxorubicinTafasitamabObinutuzumabIbrutinibEtoposideWaldenström’s macroglobulinemia RituximabGemcitabineOxaliplatinTisagenlecleucel Lisocabtagene maraleucelZanubrutinib Axicabtagene ciloleucelProcarbazinePeripheral T-cell lymphomaVinblastineMethotrexateVincristineMORNINGSUNEORTC-1537-COBRAHD0607POLARGOLOTIS-5inMINDCaDAnCe-101ATALANTA-1EPCORE NHL-2AMPLIFYLuminICE-203FLAIRECHOSTARGLOELM-2SEQUOIAELARAEPCORE NHL-5

Your opinion matters

What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?

Related articles

ASH 2024: Top abstracts in lymphoma and CLL

ASH 2024: Top abstracts in lymphoma and CLL

To help navigate the exciting content being presented at the 2024 ASH Annual Meeting, the Lymphoma Hub Steering Committee have provided their recommendations for the t...

Dec 3, 2024

#ASCO25: Congress coverage from the Lymphoma Hub

#ASCO25: Congress coverage from the Lymphoma Hub

Stay up to date with the latest developments in lymphoma and CLL with the Lymphoma Hub’s live social media coverage from the 2025 ASCO Annual Meeting, May 30 – Ju...

Jun 6, 2025

Newsletter

Subscribe to get the best content delivered to your inbox